Literature DB >> 18052554

The effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion.

Stephen V Faraone1, Himanshu P Upadhyaya.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is known to be a strong risk factor for substance use disorders (SUD) in adolescence and in adulthood. Research shows that stimulant treatment does not increase the risk of SUD in adolescents or adults with ADHD but rather that stimulant treatments may have a protective effect. However, 2 in 10 youths with ADHD misuse their medication. Recent evidence suggests that slow uptake of medication in the brain allows for effective treatment without patients experiencing the euphoric qualities of immediate-release agents that lead to abuse or diversion. As a result, extended-release products and different formulations, such as lisdexamfetamine dimesylate (LDX), are less likely to be misused and diverted and may have lower abuse potential.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18052554     DOI: 10.4088/jcp.1107e28

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

1.  Strain differences in self-administration of methylphenidate and sucrose pellets in a rat model of attention-deficit hyperactivity disorder.

Authors:  Julie A Marusich; William Travis McCuddy; Joshua S Beckmann; Cassandra D Gipson; Michael T Bardo
Journal:  Behav Pharmacol       Date:  2011-12       Impact factor: 2.293

2.  Novel Formulations of ADHD Medications: Stimulant Selection and Management.

Authors:  Ann C Childress
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

Review 3.  European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Authors:  Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson
Journal:  BMC Psychiatry       Date:  2010-09-03       Impact factor: 3.630

Review 4.  The identification and management of ADHD offenders within the criminal justice system: a consensus statement from the UK Adult ADHD Network and criminal justice agencies.

Authors:  Susan J Young; Marios Adamou; Blanca Bolea; Gisli Gudjonsson; Ulrich Müller; Mark Pitts; Johannes Thome; Philip Asherson
Journal:  BMC Psychiatry       Date:  2011-02-18       Impact factor: 3.630

Review 5.  Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.

Authors:  Christopher Steer; Jan Froelich; César A Soutullo; Mats Johnson; Monica Shaw
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 6.497

Review 6.  Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents.

Authors:  Nicholas T Bello
Journal:  Patient Prefer Adherence       Date:  2015-06-30       Impact factor: 2.711

7.  An online survey of Turkish psychiatrists' attitudes about and experiences of adult attention deficit hyperactivity disorder in clinical practice.

Authors:  Murat Altın; Gamze Ergil Altın; Bengi Semerci
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-04       Impact factor: 2.570

8.  Management of attention deficit/hyperactivity disorder and the use of stimulants in prison. Evaluation of the risks and benefits.

Authors:  A Fructuoso
Journal:  Rev Esp Sanid Penit       Date:  2019

Review 9.  Pharmacological Neuroenhancement: Current Aspects of Categorization, Epidemiology, Pharmacology, Drug Development, Ethics, and Future Perspectives.

Authors:  Johanna Daubner; Muhammad Imran Arshaad; Christina Henseler; Jürgen Hescheler; Dan Ehninger; Karl Broich; Oliver Rawashdeh; Anna Papazoglou; Marco Weiergräber
Journal:  Neural Plast       Date:  2021-01-13       Impact factor: 3.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.